Mutual Alleges Mucinex Monopoly In Extended-Release Guaifenesin

 
• By Eileen Francis

Mutual Pharmaceutical alleges in an antitrust suit that RB attempts to monopolize the extended-release guaifenesin OTC category with its Mucinex product. The suit says Mutual has lost “tens of millions” due to RB's failure to honor a contract to supply an “authorized generic” of the product.

RB’s attempt to monopolize the extended-release guaifenesin OTC category thwarted Mutual PharmaceuticalCo. Inc.’splan to market an “authorized generic” of extended-release Mucinex, according to an antitrust complaint.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America